{"Title": ["BUZZ-U.S. STOCKS ON THE MOVE-Spotify, First Solar, JanOne, Designer Brands", "BUZZ-U.S. STOCKS ON THE MOVE-Quicklogic, Fox Factory, Francesca's Holdings", "BUZZ-U.S. STOCKS ON THE MOVE-Orion Group, Carnival Corp", "CYCN Awaits Sickle Cell Disease Data, TTPH Finalizes Its Suitor, ADMS Faces FDA In Feb", "After Market Hours: Dynagas, Adamas Pharma, Gogo Gain; Slack Tech, Cinedigm Down", "10 Worst-Performing Stocks of 2019", "Tuesday Sector Laggards: Advertising, Drugs", "Will These Pharma Stocks Soar Or Swoon This Month? (ACER, ACST, ADMS, SLGL)", "BUZZ-U.S. STOCKS ON THE MOVE-Spotify, First Solar, JanOne, Designer Brands", "Why Adamas Pharmaceuticals Shares Are Crashing Today", "Mid-Day Market Update: Ctrip.Com Climbs Following Upbeat Q4 Results; Barnes & Noble Education Shares Slide", "Health Care Sector Update for 03/05/2019: ADMS, NNVC, NVTA, JNJ, PFE, MRK, ABT, AMGN", "Pre-Market Most Active for Mar 5, 2019 : ACB, TGT, QQQ, SQQQ, SAN, NIO, VOD, JMU, VEON, ADMS, HUYA, CRM", "Health Care Sector Update for 03/05/2019: PMD,ACB,ACB.TO,AMRN,ADMS", "Mid-Afternoon Market Update: YY Rises After Q4 Results; Atlas Financial Shares Fall", "Health Care Sector Update for 03/05/2019: AMRN,ACB,ACB.TO,ADMS", "Adamas Pharmaceuticals Inc (ADMS) Q2 2019 Earnings Call Transcript", "After-Hours Earnings Report for March 4, 2019 : CRM, CTRP, YY, ADUS, VNET, GRBK, PKOH, STRL, CLAR, ADMS, GAIA, CPTA", "Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?", "Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release", "Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?", "Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?", "AptarGroup (ATR) to Report Q4 Earnings: What's in Store?", "Milacron (MCRN) to Report Q4 Earnings: What's in Store?", "Adamas Pharmaceuticals Inc (ADMS) Q4 2018 Earnings Conference Call Transcript", "After-Hours Earnings Report for March 4, 2019 : CRM, CTRP, YY, ADUS, VNET, GRBK, PKOH, STRL, CLAR, ADMS, GAIA, CPTA", "Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November", "The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today", "Why Adamas Pharmaceuticals, Inc. Stock Sank in September", "Notable Friday Option Activity: ADMS, POST, AAOI", "Commit To Purchase Adamas Pharmaceuticals At $20, Earn 21.1% Annualized Using Options", "Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals", "Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?", "Adamas Pharmaceuticals (ADMS) Q4 2017 Earnings Conference Call Transcript", "Here's Why Adamas Pharmaceuticals Dropped Today", "FDA Accepts Acorda's NDA for Parkinson's Disease Candidate", "Why Adamas Pharmaceuticals Fell Today", "Parkinson's Disease Space Again Under Spotlight This Week", "4 Biotech/Pharma Stocks to Watch", "Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up", "New Strong Sell Stocks for February 26th", "Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija", "Acorda Stock Up Despite Phase III Trial on Tozadenant Stops", "Acorda Reports Death in Parkinson's Trials, Stock Down 40%", "Steven Cohen Takes Stake in Karyopharm Therapeutics", "3 Biotech Stocks That Soared This Week: Are They Buys?", "What's Causing Adamas Pharmaceuticals to Spike Higher Today", "Stocks Flashing Renewed Technical Strength: Adamas Pharmaceuticals", "7 Stocks Ready to Jump Another 30% in 2018", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 82", "Adamas Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating", "Stocks To Watch: Adamas Pharmaceuticals Sees Relative Strength Rating Jump To 92", "Noteworthy Friday Option Activity: ADMS, CZR, AL", "Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark", "Could These 2 Biotech Stocks Really Double Your Money?", "Pioneering Adamas Pharmaceuticals - Bhavneesh Sharma's Idea Of The Month", "Why Adamas Pharmaceuticals Inc. Jumped Higher Today", "Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars", "Health Care Sector Update for 08/25/2017: JNJ, PFE, ABT, MRK, AMGN, XOMA, VEEV, ADMS, NVS", "Pre-Market Most Active for Aug 25, 2017 : ADMS, TVIX, GME, KMDA, SNE, ANF, SNY, BP, BAC, USLV, XIV, SQQQ", "Why Urban Outfitters, Pure Storage, and Adamas Pharmaceuticals Jumped Today", "Adamas Pharmaceuticals (ADMS) Stock Soars 41% After FDA Approval", "Energy Sector Update for 08/25/2017: ADMS,DMTX,ACET", "Midday Update: Stocks Back Off Highs as Wall Street Shifts Focus to ECB's Draghi", "Why Adamas Pharmaceuticals Inc Stock Skyrocketed Today", "Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)", "Noteworthy Thursday Option Activity: PRU, PEP, ADMS", "Largest Insider Buys and Sales of the Week", "Adamas Provides Positive Long-term Data on Parkinson's Drug", "Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study", "Technology Sector Update for 04/18/2017: ADMS,XOMA,MATN", "Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%", "Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options", "Mylan/Biocon's Herceptin Biosimilar Phase III Data Published", "Mylan (MYL) Launches Authorized Generic EpiPen at $300", "Is Cooper Companies (COO) Poised for Earnings Beat in Q4?", "Is Mallinckrodt (MNK) Poised for a Beat in Q4 Earnings?", "Why Impax Laboratories (IPXL) Could Be Positioned for a Slump", "Patterson Companies (PDCO) Q2 Earnings: What's in Store?", "Can Veeva Systems (VEEV) Pull a Surprise in Q3 Earnings?", "Mylan (MYL) Announces Multiple Generic Launches in the U.S.", "Allergan/Adamas Launch New Dosage Strengths of Namzaric", "Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III", "Health Care Sector Update for 09/21/2016: ADMS,ABEO,MIRN", "Allergan, Adamas Agree to Settle Namzaric Patent Litigation", "Why Adamas Pharmaceuticals (ADMS) Stock Might be a Great Pick", "We Did The Math IBB Can Go To $383", "Why Adamas Pharmaceuticals Dropped 25.3% in February", "Moving Average Crossover Alert: Adamas Pharma (ADMS)", "Company News for December 24, 2015", "Pre-Market Most Active for Dec 24, 2015 : SUNE, XRS, RLYP, TVIX, BP, FCX, NKE, SKM, XIV, QQQ, ADMS, YNDX", "Adamas (ADMS) Surges on Positive Data on Lead Candidate", "Health Care Sector Update for 12/24/2015: GWPH,AGEN,RVNA", "Here's Why Adamas Pharmaceuticals' Stock Soared Today", "Pre-Market Most Active for Dec 23, 2015 : TVIX, XIV, MT, MU, BP, SUNE, FCX, QQQ, LYG, BAC, ADMS, CELG", "Why Freeport-McMoRan, Adamas Pharmaceuticals, and Denbury Resources Jumped Today", "Adamas Pharmaceuticals (ADMS) Shares March Higher, Can It Continue?", "Company News for December 24, 2015", "Pre-Market Most Active for Dec 24, 2015 : SUNE, XRS, RLYP, TVIX, BP, FCX, NKE, SKM, XIV, QQQ, ADMS, YNDX", "Versartis (VSAR) Up on Partial Hold Lift on Lead Candidate - Analyst Blog", "Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog", "Teva, Xenon Pain Drug Fails Phase IIb Study, Xenon Slumps - Analyst Blog", "Corium International (CORI) in Focus: Stock Falls by 5.2% - Tale of the Tape", "Adamas Pharmaceuticals (ADMS) Shares March Higher, Can It Continue? - Tale of the Tape", "Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape", "Adamas Pharmaceuticals, Inc. (ADMS) Jumps: Stock Rises 5.3% - Tale of the Tape", "Corium International (CORI) in Focus: Stock Rises 7% - Tale of the Tape", "Zacks Rank #1 Additions for Monday - Tale of the Tape", "Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog", "3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.", "Company News for December 26, 2014 - Corporate Summary", "Adamas Pharmaceuticals (ADMS) Jumps: Stock Gains 9.9% - Tale of the Tape", "Adamas (ADMS) Worth Watching: Stock Moves 5.5% Higher - Tale of the Tape", "After Hours Most Active for Oct 7, 2014 : BCS, GRT, CPWR, RF, ABB, KOG, LOPE, BAC, QQQ, ADMS, TIBX, MSFT", "Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO", "Ice Buckets and IPOs: 6 biotechs targeting CNS diseases", "Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog", "Will Forest Labs Retain Namenda Market Share? - Analyst Blog", "Milestone Payments for Adamas - Analyst Blog", "Adamas Pharmaceuticals prices IPO at $16, the low end of the range", "Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog", "CNS disorders pharmaceutical Adamas Pharmaceuticals sets terms for $51 million IPO", "16 US IPOs planned for the week of Apr 7"], "Elapsed Time": ["JUN 18, 2020", "JUN 18, 2020", "JUN 18, 2020", "JUN 4, 2020", "JUN 4, 2020", "DEC 23, 2019", "DEC 17, 2019", "DEC 15, 2019", "JUN 18, 2020", "MAR 5, 2019", "MAR 5, 2019", "MAR 5, 2019", "MAR 5, 2019", "MAR 5, 2019", "MAR 5, 2019", "MAR 5, 2019", "AUG 12, 2019", "MAR 4, 2019", "FEB 26, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 20, 2019", "FEB 18, 2019", "FEB 18, 2019", "MAR 4, 2019", "JAN 10, 2019", "DEC 11, 2018", "NOV 2, 2018", "OCT 12, 2018", "AUG 3, 2018", "MAR 12, 2018", "MAR 12, 2018", "FEB 7, 2019", "FEB 25, 2018", "FEB 23, 2018", "FEB 21, 2018", "FEB 20, 2018", "JAN 11, 2018", "JAN 10, 2018", "JAN 10, 2018", "FEB 26, 2018", "DEC 8, 2017", "NOV 21, 2017", "NOV 16, 2017", "NOV 7, 2017", "NOV 4, 2017", "NOV 1, 2017", "OCT 31, 2017", "DEC 19, 2017", "OCT 30, 2017", "OCT 26, 2017", "OCT 6, 2017", "SEP 29, 2017", "SEP 29, 2017", "SEP 6, 2017", "AUG 28, 2017", "OCT 30, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 25, 2017", "AUG 21, 2017", "AUG 17, 2017", "JUN 23, 2017", "JUN 9, 2017", "MAY 23, 2017", "APR 18, 2017", "JAN 9, 2017", "AUG 23, 2017", "DEC 28, 2016", "DEC 19, 2016", "DEC 7, 2016", "NOV 23, 2016", "NOV 21, 2016", "NOV 17, 2016", "NOV 17, 2016", "DEC 30, 2016", "SEP 23, 2016", "SEP 21, 2016", "SEP 21, 2016", "SEP 1, 2016", "JUL 7, 2016", "MAY 5, 2016", "MAR 7, 2016", "NOV 11, 2016", "DEC 24, 2015", "DEC 24, 2015", "DEC 24, 2015", "DEC 24, 2015", "DEC 23, 2015", "DEC 23, 2015", "DEC 23, 2015", "JAN 7, 2016", "DEC 24, 2015", "JUL 7, 2015", "JUL 7, 2015", "JUL 2, 2015", "JUL 2, 2015", "JUN 22, 2015", "JUN 18, 2015", "JUL 28, 2015", "JUN 3, 2015", "MAY 21, 2015", "MAY 18, 2015", "APR 13, 2015", "JAN 3, 2015", "DEC 26, 2014", "DEC 26, 2014", "JUN 11, 2015", "OCT 7, 2014", "SEP 8, 2014", "AUG 26, 2014", "JUN 19, 2014", "JUN 13, 2014", "MAY 22, 2014", "APR 9, 2014", "DEC 26, 2014", "MAR 26, 2014", "APR 7, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-spotify-first-solar-janone-designer-brands-2020-06-18", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-quicklogic-fox-factory-francescas-holdings-2020-06-18", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-orion-group-carnival-corp-2020-06-18", "https://www.nasdaq.com/articles/cycn-awaits-sickle-cell-disease-data-ttph-finalizes-its-suitor-adms-faces-fda-in-feb-2020", "https://www.nasdaq.com/articles/after-market-hours%3A-dynagas-adamas-pharma-gogo-gain-slack-tech-cinedigm-down-2020-06-04", "https://www.nasdaq.com/articles/10-worst-performing-stocks-of-2019-2019-12-23", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-advertising-drugs-2019-12-17", "https://www.nasdaq.com/articles/will-these-pharma-stocks-soar-or-swoon-this-month-acer-acst-adms-slgl-2019-12-15", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-spotify-first-solar-janone-designer-brands-2020-06-18", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-shares-are-crashing-today-2019-03-05", "https://www.nasdaq.com/articles/mid-day-market-update-ctripcom-climbs-following-upbeat-q4-results-barnes-noble-education", "https://www.nasdaq.com/articles/health-care-sector-update-03052019-adms-nnvc-nvta-jnj-pfe-mrk-abt-amgn-2019-03-05", "https://www.nasdaq.com/articles/pre-market-most-active-mar-5-2019-acb-tgt-qqq-sqqq-san-nio-vod-jmu-veon-adms-huya-crm-2019", "https://www.nasdaq.com/articles/health-care-sector-update-03052019-pmdacbacbtoamrnadms-2019-03-05", "https://www.nasdaq.com/articles/mid-afternoon-market-update-yy-rises-after-q4-results-atlas-financial-shares-fall-2019-03", "https://www.nasdaq.com/articles/health-care-sector-update-03052019-amrnacbacbtoadms-2019-03-05", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-inc-adms-q2-2019-earnings-call-transcript-2019-08-12", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-4-2019-crm-ctrp-yy-adus-vnet-grbk-pkoh-strl-clar-adms", "https://www.nasdaq.com/articles/will-rd-focus-fuel-dentsply-sironas-xray-earnings-in-q4-2019-02-26", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-expected-to-beat-earnings-estimates%3A-what-to-know-ahead-of-q4", "https://www.nasdaq.com/articles/tenet-healthcare-thc-q4-earnings%3A-whats-in-the-offing-2019-02-20", "https://www.nasdaq.com/articles/can-segmental-growth-fuel-veeva-systems-veev-q4-earnings-2019-02-20", "https://www.nasdaq.com/articles/aptargroup-atr-to-report-q4-earnings%3A-whats-in-store-2019-02-18", "https://www.nasdaq.com/articles/milacron-mcrn-to-report-q4-earnings%3A-whats-in-store-2019-02-18", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-inc-adms-q4-2018-earnings-conference-call-transcript-2019-03-04", "https://www.nasdaq.com/articles/heres-why-these-small-cap-pharma-stocks-lost-much-45-december-2019-01-10", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-inc-stock-continued-slide-november-2018-12-11", "https://www.nasdaq.com/articles/probable-reason-why-adamas-pharmaceuticals-inc-down-big-today-2018-11-02", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-inc-stock-sank-september-2018-10-12", "https://www.nasdaq.com/articles/notable-friday-option-activity-adms-post-aaoi-2018-08-03", "https://www.nasdaq.com/articles/commit-purchase-adamas-pharmaceuticals-20-earn-211-annualized-using-options-2018-03-12", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-astrazeneca-bayer-dr.-reddys-laboratories-teva", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-molina-healthcare-moh-q4-earnings-2019-02-07", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-q4-2017-earnings-conference-call-transcript-2018-02-25", "https://www.nasdaq.com/articles/heres-why-adamas-pharmaceuticals-dropped-today-2018-02-23", "https://www.nasdaq.com/articles/fda-accepts-acordas-nda-for-parkinsons-disease-candidate-2018-02-21", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-fell-today-2018-02-20", "https://www.nasdaq.com/articles/parkinsons-disease-space-again-under-spotlight-this-week-2018-01-11", "https://www.nasdaq.com/articles/4-biotechpharma-stocks-watch-2018-01-10", "https://www.nasdaq.com/articles/adamas-adms-launches-dyskinesia-drug-in-the-us-stock-up-2018-01-10", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-february-26th-2018-02-26", "https://www.nasdaq.com/articles/acorda-resubmits-nda-for-parkinsons-disease-candidate-inbrija-2017-12-08", "https://www.nasdaq.com/articles/acorda-stock-up-despite-phase-iii-trial-on-tozadenant-stops-2017-11-21", "https://www.nasdaq.com/articles/acorda-reports-death-in-parkinsons-trials-stock-down-40-2017-11-16", "https://www.nasdaq.com/articles/steven-cohen-takes-stake-karyopharm-therapeutics-2017-11-07", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2017-11-04", "https://www.nasdaq.com/articles/whats-causing-adamas-pharmaceuticals-spike-higher-today-2017-11-01", "https://www.nasdaq.com/articles/stocks-flashing-renewed-technical-strength-adamas-pharmaceuticals-2017-10-31", "https://www.nasdaq.com/articles/7-stocks-ready-to-jump-another-30-in-2018-2017-12-19", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-82-2017-10-30", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-clears-technical-benchmark-hitting-80-plus-rs-rating-2017-10-26", "https://www.nasdaq.com/articles/stocks-watch-adamas-pharmaceuticals-sees-relative-strength-rating-jump-92-2017-10-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-adms-czr-al-2017-09-29", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark-2017-09-29", "https://www.nasdaq.com/articles/could-these-2-biotech-stocks-really-double-your-money-2017-09-06", "https://www.nasdaq.com/articles/pioneering-adamas-pharmaceuticals-bhavneesh-sharmas-idea-month-2017-08-28", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-inc-jumped-higher-today-2017-10-30", "https://www.nasdaq.com/articles/adamas-adms-dyskinesia-drug-gets-fda-approval-stock-soars-2017-08-25", "https://www.nasdaq.com/articles/health-care-sector-update-08252017-jnj-pfe-abt-mrk-amgn-xoma-veev-adms-nvs-2017-08-25", "https://www.nasdaq.com/articles/pre-market-most-active-aug-25-2017-adms-tvix-gme-kmda-sne-anf-sny-bp-bac-uslv-xiv-sqqq", "https://www.nasdaq.com/articles/why-urban-outfitters-pure-storage-and-adamas-pharmaceuticals-jumped-today-2017-08-25", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-stock-soars-41-after-fda-approval-2017-08-25", "https://www.nasdaq.com/articles/energy-sector-update-08252017-admsdmtxacet-2017-08-25", "https://www.nasdaq.com/articles/midday-update-stocks-back-highs-wall-street-shifts-focus-ecbs-draghi-2017-08-25", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-inc-stock-skyrocketed-today-2017-08-25", "https://www.nasdaq.com/articles/falling-earnings-estimates-signal-weakness-ahead-for-adamas-adms-2017-08-21", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-pru-pep-adms-2017-08-17", "https://www.nasdaq.com/articles/largest-insider-buys-and-sales-week-2017-06-23", "https://www.nasdaq.com/articles/adamas-provides-positive-long-term-data-on-parkinsons-drug-2017-06-09", "https://www.nasdaq.com/articles/adamas-epilepsy-drug-shows-positive-result-in-phase-ia-study-2017-05-23", "https://www.nasdaq.com/articles/technology-sector-update-04182017-admsxomamatn-2017-04-18", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-in-focus%3A-stock-up-5.4-2017-01-09", "https://www.nasdaq.com/articles/implied-volatility-surging-for-adamas-pharmaceuticals-adms-stock-options-2017-08-23", "https://www.nasdaq.com/articles/mylan-biocons-herceptin-biosimilar-phase-iii-data-published-2016-12-28", "https://www.nasdaq.com/articles/mylan-myl-launches-authorized-generic-epipen-at-%24300-2016-12-19", "https://www.nasdaq.com/articles/is-cooper-companies-coo-poised-for-earnings-beat-in-q4-2016-12-07", "https://www.nasdaq.com/articles/is-mallinckrodt-mnk-poised-for-a-beat-in-q4-earnings-2016-11-23", "https://www.nasdaq.com/articles/why-impax-laboratories-ipxl-could-be-positioned-for-a-slump-2016-11-21", "https://www.nasdaq.com/articles/patterson-companies-pdco-q2-earnings%3A-whats-in-store-2016-11-17", "https://www.nasdaq.com/articles/can-veeva-systems-veev-pull-a-surprise-in-q3-earnings-2016-11-17", "https://www.nasdaq.com/articles/mylan-myl-announces-multiple-generic-launches-in-the-u.s.-2016-12-30", "https://www.nasdaq.com/articles/allergan-adamas-launch-new-dosage-strengths-of-namzaric-2016-09-23", "https://www.nasdaq.com/articles/adamas-adms-parkinsons-disease-drug-positive-in-phase-iii-2016-09-21", "https://www.nasdaq.com/articles/health-care-sector-update-09212016-admsabeomirn-2016-09-21", "https://www.nasdaq.com/articles/allergan-adamas-agree-to-settle-namzaric-patent-litigation-2016-09-01", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-adms-stock-might-be-a-great-pick-2016-07-07", "https://www.nasdaq.com/articles/we-did-math-ibb-can-go-383-2016-05-05", "https://www.nasdaq.com/articles/why-adamas-pharmaceuticals-dropped-253-february-2016-03-07", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-adamas-pharma-adms-2016-11-11", "https://www.nasdaq.com/articles/company-news-for-december-24-2015-2015-12-24", "https://www.nasdaq.com/articles/pre-market-most-active-dec-24-2015-sune-xrs-rlyp-tvix-bp-fcx-nke-skm-xiv-qqq-adms-yndx", "https://www.nasdaq.com/articles/adamas-adms-surges-on-positive-data-on-lead-candidate-2015-12-24", "https://www.nasdaq.com/articles/health-care-sector-update-12242015-gwphagenrvna-2015-12-24", "https://www.nasdaq.com/articles/heres-why-adamas-pharmaceuticals-stock-soared-today-2015-12-23", "https://www.nasdaq.com/articles/pre-market-most-active-dec-23-2015-tvix-xiv-mt-mu-bp-sune-fcx-qqq-lyg-bac-adms-celg-2015", "https://www.nasdaq.com/articles/why-freeport-mcmoran-adamas-pharmaceuticals-and-denbury-resources-jumped-today-2015-12-23", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-shares-march-higher-can-it-continue-2016-01-07", "https://www.nasdaq.com/articles/company-news-for-december-24-2015-2015-12-24", "https://www.nasdaq.com/articles/versartis-vsar-catches-eye%3A-stock-moves-29.4-higher-tale-of-the-tape-2015-07-07", "https://www.nasdaq.com/articles/versartis-vsar-up-on-partial-hold-lift-on-lead-candidate-analyst-blog-2015-07-07", "https://www.nasdaq.com/articles/kite-pharma-gains-after-striking-kte-c19-development-deal-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/teva-xenon-pain-drug-fails-phase-iib-study-xenon-slumps-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/corium-international-cori-in-focus%3A-stock-falls-by-5.2-tale-of-the-tape-2015-06-22", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-shares-march-higher-can-it-continue-tale-of-the-tape-2015-06", "https://www.nasdaq.com/articles/allergan-agn-in-focus%3A-stock-jumps-6.1-tale-of-the-tape-2015-07-28", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-inc.-adms-jumps%3A-stock-rises-5.3-tale-of-the-tape-2015-06-03", "https://www.nasdaq.com/articles/corium-international-cori-in-focus%3A-stock-rises-7-tale-of-the-tape-2015-05-21", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-monday-tale-of-the-tape-2015-05-18", "https://www.nasdaq.com/articles/adamas-pharmas-lead-candidate-gets-orphan-status-in-u.s.-analyst-blog-2015-04-13", "https://www.nasdaq.com/articles/3-biotech-stocks-higher-profit-margin-gilead-sciences-inc-2015-01-03", "https://www.nasdaq.com/articles/company-news-for-december-26-2014-corporate-summary-2014-12-26", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-adms-jumps%3A-stock-gains-9.9-tale-of-the-tape-2014-12-26", "https://www.nasdaq.com/articles/adamas-adms-worth-watching%3A-stock-moves-5.5-higher-tale-of-the-tape-2015-06-11", "https://www.nasdaq.com/articles/after-hours-most-active-oct-7-2014-bcs-grt-cpwr-rf-abb-kog-lope-bac-qqq-adms-tibx-msft", "https://www.nasdaq.com/articles/diabetesalzheimers-biotech-vitae-pharmaceuticals-sets-terms-60-million-ipo-2014-09-08", "https://www.nasdaq.com/articles/ice-buckets-and-ipos-6-biotechs-targeting-cns-diseases-2014-08-26", "https://www.nasdaq.com/articles/forest-laboratories-nabs-pediatric-exclusivity-for-namenda-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/will-forest-labs-retain-namenda-market-share-analyst-blog-2014-06-13", "https://www.nasdaq.com/articles/milestone-payments-for-adamas-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/adamas-pharmaceuticals-prices-ipo-16-low-end-range-2014-04-09", "https://www.nasdaq.com/articles/actavis-alzheimers-drug-approved-bystolic-gets-crl-analyst-blog-2014-12-26", "https://www.nasdaq.com/articles/cns-disorders-pharmaceutical-adamas-pharmaceuticals-sets-terms-51-million-ipo-2014-03-26", "https://www.nasdaq.com/articles/16-us-ipos-planned-week-apr-7-2014-04-07"], "Content": []}